TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05094323
Drug: Local wound infiltration with isobaric bupivacaine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive local wound infiltration with isobaric bupivacaine.
Study: NCT05094323
Drug: Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
Study: NCT06636552
Drug: Daratumumab (Subcutaneously)
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1
Study: NCT05787418
Drug: HH-120 Nasal Spray
Normalized name: HH-009
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HH-120 nasal spray 8 times per day for 7 consecutive days
Study: NCT05369052
Drug: Linezolid (IV and PO)
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
Study: NCT05542355
Drug: EXL01
Normalized name: Elexacaftor
DrugBank: Elexacaftor (DB15444)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
Study: NCT06543979
Drug: lubiprostone , single arm
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: laxative
Study: NCT04723875
Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin
Normalized name: Medicated Pad or Tape
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Study: NCT04639414
Drug: Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d compared to matching placebo after 48-week treatment.
Study: NCT04639414
Drug: Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide
Normalized name: semaglutide Pen Injector
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Measurement of the effect of empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Study: NCT04639414
Drug: Placebo matching empagliflozin and placebo pen injector matching semaglutide
Normalized name: semaglutide Pen Injector
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Measurement of the effect of the combined treatment with semaglutide 1mg/week and empagliflozin 10 mg/d OR empagliflozin monotherapy 10mg/d compared to matching placebo after 48-week treatment.
Study: NCT06498752
Drug: PD-1 monoclonal antibody consolidation therapy
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
Study: NCT04452461
Drug: Gemcitabine / Nab-paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
Study: NCT05996003
Drug: NS-089/NCNP-02
DrugBank: Brogidirsen (DB18884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1
Study: NCT05994235
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosunetuzumab will be administered in weekly dose increments (step-up dosing) during Cycle 1 and then on Day 1 of each cycle. Mosunetuzumab will be given in 28-day cycles for up to 12 cycles. Mosunetuzumab will be administered SC at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15 in Cycle 1. Beginning with Cycle 2, it will be administered SC at the dose of 45 mg on Day 1. Each cycle lasts 4 weeks.
Study: NCT05994235
Drug: Tazemetostat Pill
Normalized name: tazemetostat Pill
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tazemetostat will be administered by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation until disease progression, unacceptable toxicity, or consent is withdrawn. Patients will remain on tazemetostat for up to twelve 28-day cycles from initiation of mosunetuzumab.
Study: NCT06635317
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/day orally for 25 days
Study: NCT06635317
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
Study: NCT06577532
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 antibody, administered intravenously
Study: NCT04740294
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Randomized to receive either magnesium sulfate or normal saline placebo.
Study: NCT06186648
Drug: Glofitamab + Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone
Study: NCT04968938
Drug: midomafetamine
Normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
Study: NCT06393881
Drug: UI059
Normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: take UI059 once a day for 7 days
Study: NCT05441930
Drug: Levofloxacin Ocular Implant
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
Study: NCT05441930
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
Study: NCT06010589
Drug: DWC202310 and DWC202311
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Co-administration of DWC202310 and DWC202311
Study: NCT04247750
Drug: Sirolimus 0.5 mg
Normalized name: sirolimus 0.5 MG
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily administration of 1 or more tablets
Study: NCT05564286
Drug: Fosaprepitant
Normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
Study: NCT05564286
Drug: tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received tropisetron 5mg on day 1.
Study: NCT05564286
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: .All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
Study: NCT04798391
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Steroids and analgesics
Study: NCT05477797
Drug: Ixazomib DX/Lenalidomide DX
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
Study: NCT05321251
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm description
Study: NCT05713318
Drug: HH-120 nasal spray
Normalized name: HH-009
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.
Study: NCT05713318
Drug: HH-120 nasal spray
Normalized name: HH-009
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.
Study: NCT05688579
Drug: Mineralocorticoid Receptor Antagonists(MRAs)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
Study: NCT05596968
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study: NCT05799443
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
Study: NCT05505838
Drug: Patisiran
Normalized name: patisiran
DrugBank: Patisiran (DB14582)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patisiran administered by intravenous (IV) infusion
Study: NCT05799443
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.
Study: NCT05799443
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
Study: NCT04764396
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FNB will be performed as current standard methods in the medical procedure unit without the use of heparin priming. Pass 1, 2, and 3 will be collected in separate jars and sent to pathology, as per standard clinical procedures. Between passes, after tissue is extracted from the needle, the needle will be flushed saline and or air as per current standards of care.
Study: NCT05008679
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at a dose of 75 mg twice daily
Study: NCT04788108
Drug: Dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone tablet
Study: NCT03972124
Drug: CBD 100 mg OD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD oil - purified to \<1% THC in soft-gel capsules
Study: NCT03972124
Drug: CBD 200 mg OD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD oil - purified to \<1% THC in soft-gel capsules
Study: NCT00002218
Drug: CI-1012
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06433180
Drug: Administration of fecal microbiota transplantation ( FMT capsules)
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.
Study: NCT05328921
Drug: Antihistaminics
Normalized name: Ahist Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
Study: NCT06669078
Drug: Nal-lRl+Oxaliplain+5- FU +PD 1
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
Study: NCT06669078
Drug: Nal-lRl+Oxaliplain+5- FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
Study: NCT06161909
Drug: sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg fixed dose Q3W,1 year
Study: NCT03762395
Drug: CXA-10
Normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks of treatment with 150 mg/day of orally administered CXA-10
Study: NCT06138574
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil
Study: NCT04589819
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
Study: NCT05820724
Drug: 18F- DCFPyl Injection
Normalized name: (18F)DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCFPyL is a PSMA imaging ligand that was developed to enhance the detection of small lesions in the prostate or other pelvic areas. 18F- DCFPyl Injection will be administered prior to the PSMA PET/CT via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access under the direct supervision of study personnel.
Study: NCT06535685
Drug: Romiplostim
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.
Study: NCT04759820
Drug: injecting Carbon Nanoparticles Suspension
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injecting Carbon Nanoparticles Suspension for lymph node detection
Study: NCT04759820
Drug: Injecting indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injecting indocyanine green for lymph node detection
Study: NCT06459687
Drug: Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w.
Study: NCT06459687
Drug: Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w.
Study: NCT06555237
Drug: Trametinib tablet
Normalized name: Trametinib Tablets
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametynib orally once daily in 0,025mg/kg dose
Study: NCT04608474
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
Study: NCT05059418
Drug: Clonazepam 0.5 MG
Normalized name: clonazepam 0.5 MG
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical treatment of oral mucosa with lozenge pill
Study: NCT05059418
Drug: Capsaicin Topical
Normalized name: capsaicin topical
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical treatment of oral mucosa with capsaicin rinse
Study: NCT05255913
Drug: Nanosilver
Normalized name: Nanosilver
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: preventive material for arresting caries
Study: NCT05255913
Drug: Silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preventive material for arresting caries
Study: NCT06520319
Drug: 68Ga-MGS5
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
Study: NCT06055829
Drug: Insulin injection and blood glucose
Normalized name: glucose Injection
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
Study: NCT05127421
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5% applied twice a day (BID)
Study: NCT05834764
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
Study: NCT06394518
Drug: TNP-2092 for injection
Normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
Study: NCT05403541
Drug: Batoclimab 680 mg SC weekly
Normalized name: selinexor
DrugBank: Batoclimab (DB16104)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT05403541
Drug: Batoclimab 340 mg SC weekly
Normalized name: selinexor
DrugBank: Batoclimab (DB16104)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT05705570
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25mg/m\^2 IV on days -5 to -3
Study: NCT05403541
Drug: Batoclimab 340 mg SC bi-weekly
Normalized name: selinexor
DrugBank: Batoclimab (DB16104)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT04954339
Drug: Aatezolizumab plus Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two cycles of naeoadjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) prior to surgical resection and four cycles of adjuvant atezolizumab (1200 mg) plus bevacizumab (15 mg/kg) after the surgery will be administered.
Study: NCT04923919
Drug: Anti-CLL1 CART cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, patients with acute myeloid leukemia were treated with autologous anti-CLL1 CAR T cells by a single, intravenous infusion.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the efficacy of CAR T cells.
Study: NCT06161844
Drug: semaglutide injection (HD1916)
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
Study: NCT06459921
Drug: SOX+Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients would be allocated to the SOX+Sintilimab group.
Study: NCT06459921
Drug: FLOT+Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients would be allocated to the FLOT+Sintilimab group.
Study: NCT05284994
Drug: TQ-B3525 Tablets, Osimertinib Mesylate Tablets
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
Study: NCT05005975
Drug: MT-7117
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-7117
Study: NCT04626791
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04626791
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT04626791
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV